Format

Send to

Choose Destination
Haematologica. 2018 Dec 4. pii: haematol.2018.198820. doi: 10.3324/haematol.2018.198820. [Epub ahead of print]

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow-up of the Swedish compassionate use cohort.

Author information

1
Department of Oncology-Pathology, Karolinska Institutet; maria.winqvist@sll.se.
2
Department of Hemaology, Borås Hospital, Borås.
3
Department of Oncology-Pathology, Karolinska Institutet, Stockholm.
4
Department of Hematology, Lund University Hospital, Lund.
5
Department of Hematology, Sunderby Hospital, Sunderbyn-Luleå.
6
Department of Hematology, Uppsala University Hospital, Uppsala.
7
Department of Internal Medicine, Karolinska Institutet, Stockholm.
8
Department of Hematology, Linköping University Hospital, Linköping, Sweden.
9
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
10
Department of Radiation Sciences, Oncology, Umeå University, Umeå.

KEYWORDS:

Chronic Lymphocytic Leukemia; ibrutinib; real-world

PMID:
30514799
DOI:
10.3324/haematol.2018.198820
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center